Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
N Engl J Med ; 386(9): 861-868, 2022 03 03.
Article in English | MEDLINE | ID: mdl-35235727

ABSTRACT

Melioidosis, caused by the bacterium Burkholderia pseudomallei, is an uncommon infection that is typically associated with exposure to soil and water in tropical and subtropical environments. It is rarely diagnosed in the continental United States. Patients with melioidosis in the United States commonly report travel to regions where melioidosis is endemic. We report a cluster of four non-travel-associated cases of melioidosis in Georgia, Kansas, Minnesota, and Texas. These cases were caused by the same strain of B. pseudomallei that was linked to an aromatherapy spray product imported from a melioidosis-endemic area.


Subject(s)
Aromatherapy/adverse effects , Burkholderia pseudomallei/isolation & purification , Disease Outbreaks , Melioidosis/epidemiology , Aerosols , Brain/microbiology , Brain/pathology , Burkholderia pseudomallei/genetics , COVID-19/complications , Child, Preschool , Fatal Outcome , Female , Genome, Bacterial , Humans , Lung/microbiology , Lung/pathology , Male , Melioidosis/complications , Middle Aged , Phylogeny , Shock, Septic/microbiology , United States/epidemiology
2.
PLoS One ; 13(11): e0206845, 2018.
Article in English | MEDLINE | ID: mdl-30395628

ABSTRACT

Burkholderia pseudomallei is the environmental bacillus that causes melioidosis; a disease clinically significant in Australia and Southeast Asia but emerging in tropical and sub-tropical regions around the globe. Previous studies have placed the ancestral population of the organism in Australia with a single lineage disseminated to Southeast Asia. We have previously characterized B. pseudomallei isolates from New Guinea and the Torres Strait archipelago; remote regions that share paleogeographic ties with Australia. These studies identified regional biogeographical boundaries. In this study, we utilize whole-genome sequencing to reconstruct ancient evolutionary relationships and ascertain correlations between paleogeography and present-day distribution of this bacterium in Australasia. Our results indicate that B. pseudomallei from New Guinea fall into a single clade within the Australian population. Furthermore, clades from New Guinea are region-specific; an observation possibly linked to limited recent anthropogenic influence in comparison to mainland Australia and Southeast Asia. Isolates from the Torres Strait archipelago were distinct yet scattered among those from mainland Australia. These results provide evidence that the New Guinean and Torres Strait lineages may be remnants of an ancient portion of the Australian population. Rising sea levels isolated New Guinea and the Torres Strait Islands from each other and the Australian mainland, and may have allowed long-term isolated evolution of these lineages, providing support for a theory of microbial biogeography congruent with that of macro flora and fauna. Moreover, these findings indicate that contemporary microbial biogeography theories should consider recent and ongoing impacts of globalisation and human activity.


Subject(s)
Burkholderia pseudomallei/genetics , DNA, Bacterial/genetics , Melioidosis/genetics , Phylogeny , Anthropology, Medical/history , Australasia , Australia , Burkholderia pseudomallei/pathogenicity , Genetic Variation , History, Ancient , Humans , Melioidosis/microbiology , New Guinea , Whole Genome Sequencing
3.
Microb Genom ; 3(8): e000117, 2017 08.
Article in English | MEDLINE | ID: mdl-29026657

ABSTRACT

Melioidosis is a tropical disease caused by the bacterium Burkholderia pseudomallei. Outbreaks are uncommon and can generally be attributed to a single point source and strain. We used whole-genome sequencing to analyse B. pseudomallei isolates collected from an historical 2-year long case cluster that occurred in a remote northern Australian indigenous island community, where infections were previously linked to a contaminated communal water supply. We analysed the genome-wide relatedness of the two most common multilocus sequence types (STs) involved in the outbreak, STs 125 and 126. This analysis showed that although these STs were closely related on a whole-genome level, they demonstrated evidence of multiple recombination events that were unlikely to have occurred over the timeframe of the outbreak. Based on epidemiological and genetic data, we also identified two additional patients not previously associated with this outbreak. Our results confirm the previous hypothesis that a single unchlorinated water source harbouring multiple B. pseudomallei strains was linked to the outbreak, and that increased melioidosis risk in this community was associated with Piper methysticum root (kava) consumption.


Subject(s)
Burkholderia pseudomallei/genetics , Genome, Bacterial , Melioidosis/microbiology , Australia/epidemiology , Disease Outbreaks , Humans , Kava/microbiology , Melioidosis/epidemiology , Multilocus Sequence Typing
4.
BMC Infect Dis ; 16: 388, 2016 08 09.
Article in English | MEDLINE | ID: mdl-27506202

ABSTRACT

BACKGROUND: Melioidosis caused by Burkholderia pseudomellei is an infection with protean clinical manifestations. Guillain-Barré syndrome [GBS] associated with melioidosis is very rare. CASE PRESENTATION: A 42-year-old woman with diabetes presented with abdominal pain, vomiting and intermittent fever for one month. Six months before presentation she had recurrent skin abscesses. Three months before presentation she had multiple liver abscesses which were aspirated in a local hospital. The aspirate grew "coliforms" resistant to gentamicin and sensitive to ceftazidime. On presentation she had high fever and tender hepatomegaly. Ultra Sound Scan of abdomen showed multiple liver and splenic abscesses. Based on the suggestive history and sensitivity pattern of the previous growth melioidosis was suspected and high dose meropenem was started. Antibodies to melioidin were raised at a titre of 1:10240. The growth from the aspirate of liver abscess was confirmed as Burkholderia pseudomellei by polymerase chain reaction [PCR]. After a week of treatment, patient developed bilateral lower limb weakness. Deep tendon reflexes were absent. There was no sensory loss or bladder/bowel involvement. Analysis of the cerebro-spinal fluid showed elevated proteins with no cells. There was severe peripheral neuropathy with axonal degeneration. A diagnosis of GBS was made and she was treated with plasmapharesis with marked improvement of neurological deficit. Continuation of intravenous antibiotics lead to further clinical improvement with normalization of inflammatory markers and resolution of liver and splenic abscess. Eradication therapy with oral co-trimoxazole and co-amoxyclav was started on the seventh week. Patient was discharged to outpatient clinic with a plan to continue combination of oral antibiotics for 12 weeks. At the end of 12 weeks she was well with complete neurological resolution and no evidence of a relapse. CONCLUSIONS: Guillaine Barre syndrome is a rare complication of melioidosis and should be suspected in a patient with melioidosis who develop lower limb weakness. Plasmapharesis can be successfully used to treat GBS associated with active melioidosis.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Guillain-Barre Syndrome/etiology , Melioidosis/complications , Abdominal Pain/etiology , Administration, Oral , Adult , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Anti-Bacterial Agents/administration & dosage , Burkholderia pseudomallei/genetics , Burkholderia pseudomallei/pathogenicity , Ceftazidime/therapeutic use , Drug Resistance, Bacterial/drug effects , Female , Gentamicins/therapeutic use , Humans , Injections, Intravenous , Liver Abscess/drug therapy , Liver Abscess/microbiology , Melioidosis/diagnosis , Melioidosis/drug therapy , Meropenem , Peripheral Nervous System Diseases/etiology , Polymerase Chain Reaction , Splenic Diseases/complications , Thienamycins/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
5.
Microbiologyopen ; 5(3): 512-26, 2016 06.
Article in English | MEDLINE | ID: mdl-27060604

ABSTRACT

Burkholderia is an important genus encompassing a variety of species, including pathogenic strains as well as strains that promote plant growth. We have carried out a global strategy, which combined two complementary approaches. The first one is genome guided with deep analysis of genome sequences and the second one is assay guided with experiments to support the predictions obtained in silico. This efficient screening for new secondary metabolites, performed on 48 gapless genomes of Burkholderia species, revealed a total of 161 clusters containing nonribosomal peptide synthetases (NRPSs), with the potential to synthesize at least 11 novel products. Most of them are siderophores or lipopeptides, two classes of products with potential application in biocontrol. The strategy led to the identification, for the first time, of the cluster for cepaciachelin biosynthesis in the genome of Burkholderia ambifaria AMMD and a cluster corresponding to a new malleobactin-like siderophore, called phymabactin, was identified in Burkholderia phymatum STM815 genome. In both cases, the siderophore was produced when the strain was grown in iron-limited conditions. Elsewhere, the cluster for the antifungal burkholdin was detected in the genome of B. ambifaria AMMD and also Burkholderia sp. KJ006. Burkholderia pseudomallei strains harbor the genetic potential to produce a novel lipopeptide called burkhomycin, containing a peptidyl moiety of 12 monomers. A mixture of lipopeptides produced by Burkholderia rhizoxinica lowered the surface tension of the supernatant from 70 to 27 mN·m(-1) . The production of nonribosomal secondary metabolites seems related to the three phylogenetic groups obtained from 16S rRNA sequences. Moreover, the genome-mining approach gave new insights into the nonribosomal synthesis exemplified by the identification of dual C/E domains in lipopeptide NRPSs, up to now essentially found in Pseudomonas strains.


Subject(s)
Burkholderia pseudomallei/genetics , Burkholderia pseudomallei/metabolism , Genome, Bacterial/genetics , Lipopeptides/biosynthesis , Peptide Synthases/metabolism , Siderophores/biosynthesis , Antifungal Agents/metabolism , Bacterial Proteins/biosynthesis , Base Sequence , DNA, Bacterial/genetics , Gene Expression Profiling , Lipopeptides/chemistry , RNA, Ribosomal, 16S/genetics , Sequence Analysis, DNA , Siderophores/chemistry
6.
Microbiology (Reading) ; 153(Pt 6): 1907-1915, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17526847

ABSTRACT

Burkholderia pseudomallei is a serious bacterial pathogen that can cause a lethal infection in humans known as melioidosis. In this study two of its phospholipase C (PLC) enzymes (Plc-1 and Plc-2) were characterized. Starting with a virulent strain, two single mutants were constructed, each with one plc gene inactivated, and one double mutant with both plc genes inactivated. The single plc mutants exhibited decreased extracellular PLC activity in comparison to the wild-type strain, thereby demonstrating that the two genes encoded functional extracellular PLCs. Growth comparisons between the wild-type and PLC mutants in egg-yolk-supplemented medium indicated that both PLCs contributed to egg-yolk phospholipid utilization. Both PLCs hydrolysed phosphatidylcholine and sphingomyelin but neither was haemolytic for human erythrocytes. Experimental infections of eukaryotic cells demonstrated that Plc-1 itself had no effect on plaque-forming efficiency but it had an additive effect on increasing the efficiency of Plc-2 to form plaques. Only Plc-2 had a significant role in host cell cytotoxicity. In contrast, neither Plc-1 nor Plc-2 appeared to play any role in multinucleated giant cell (MNGC) formation or induction of apoptotic death in the cells studied. These data suggested that PLCs contribute, at least in part, to B. pseudomallei virulence and support the view that Plc-1 and Plc-2 are not redundant virulence factors.


Subject(s)
Bacterial Proteins/physiology , Burkholderia pseudomallei/enzymology , Burkholderia pseudomallei/pathogenicity , Type C Phospholipases/physiology , Virulence Factors/physiology , Animals , Apoptosis , Bacterial Proteins/genetics , Burkholderia pseudomallei/genetics , Burkholderia pseudomallei/growth & development , Cell Line , Cell Survival , Egg Yolk/metabolism , Erythrocytes/microbiology , Gene Deletion , Giant Cells , HeLa Cells/cytology , Hemolysis , Humans , Macrophages/cytology , Macrophages/microbiology , Mice , Mutagenesis, Insertional , Phosphatidylcholines/metabolism , Sphingomyelins/metabolism , Type C Phospholipases/genetics , Virulence Factors/genetics
7.
J Antimicrob Chemother ; 45(6): 813-8, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10837435

ABSTRACT

Melioidosis and glanders are caused by the closely related species Burkholderia pseudomallei and Burkholderia mallei, respectively. Whereas melioidosis is a significant cause of morbidity in south-east Asia, glanders is extremely rare. The efficacies of ciprofloxacin and doxycycline were assessed against a strain of B. pseudomallei and a strain of B. mallei which were susceptible to both antimicrobials in vitro. Porton outbred mice and Syrian hamsters were given 40 mg/kg of either doxycycline or ciprofloxacin twice daily by sc injection according to one of three regimens: dosing starting 48 h before challenge and continuing for 5 days postchallenge; 5 days' therapy starting immediately after challenge; 5 days' therapy starting 24 h after challenge. Mice were challenged ip with B. pseudomallei 4845 and hamsters were challenged ip with B. mallei 23344. Antimicrobial efficacy was determined by the shift in the median lethal dose (MLD). Ciprofloxacin prophylaxis and immediate therapy both raised the MLD of B. pseudomallei to 4 x 10(6) cfu from 19 cfu in untreated animals, but therapeutic ciprofloxacin only raised the MLD to 180 cfu. The results for doxycycline were similar. Ciprofloxacin prophylaxis raised the MLD of B. mallei 23344 to 4.6 x 10(5) cfu compared with 4 cfu in untreated controls. Immediate therapy raised the MLD to 7.0 x 10(4) cfu and therapy raised the MLD to 1.6 x 10(3) cfu. All regimens of doxycycline protected hamsters against challenges of up to 2 x 10(7) cfu. Despite using a susceptible strain of B. pseudomallei, neither antimicrobial was effective when used therapeutically. The timely administration of either antimicrobial, however, was effective in preventing symptomatic infection. Doxycycline was the superior of the two antimicrobials against experimental glanders although relapse did occur in treated animals approximately 4-5 weeks after challenge.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/therapeutic use , Ciprofloxacin/therapeutic use , Doxycycline/therapeutic use , Glanders/drug therapy , Melioidosis/drug therapy , Animals , Burkholderia Infections/drug therapy , Burkholderia Infections/microbiology , Burkholderia pseudomallei/drug effects , Burkholderia pseudomallei/genetics , Burkholderia pseudomallei/pathogenicity , Cricetinae , Female , Glanders/microbiology , Melioidosis/microbiology , Mice , Microbial Sensitivity Tests , Reverse Transcriptase Polymerase Chain Reaction , Survival Analysis , Time Factors
8.
Article in Russian | MEDLINE | ID: mdl-10356737

ABSTRACT

The effect of immunization with Burkholderia pseudomallei, (Pur- and Ts), heterologous vaccines and the recombinant culture of Francisella tularensis RM2, carrying a plasmid with fragments of B. pseudomallei chromosome, was studied on four species of experimental animals, essentially differing by their sensitivity to melioidosis. B. pseudomallei mutants formed the statistically significant level of protection in subcutaneously challenged animals, moderately sensitive to melioidosis, but were not effective when tested, under the same conditions, in animals, highly sensitive to melioidosis. The effect produced by the experimental vaccines under study in animals of all species, subjected to aerogenic challenge, was leveled. The study showed good prospects for the use of tularemia vaccine with a view to create heterologous immunity to melioidosis and the possibility of its use as the basis of bivalent gene engineering vaccine.


Subject(s)
Bacterial Vaccines/immunology , Burkholderia pseudomallei/immunology , Melioidosis/prevention & control , Vaccines, Synthetic/immunology , Animals , Bacterial Vaccines/toxicity , Burkholderia pseudomallei/genetics , Burkholderia pseudomallei/pathogenicity , Chromosomes, Bacterial/genetics , Drug Evaluation, Preclinical , Francisella tularensis/genetics , Francisella tularensis/immunology , Guinea Pigs , Immunization , Mice , Mutation , Plasmids/genetics , Rats , Vaccines, Attenuated/immunology , Vaccines, Attenuated/toxicity , Vaccines, Combined/immunology , Vaccines, Combined/toxicity , Vaccines, Synthetic/toxicity , Virulence
SELECTION OF CITATIONS
SEARCH DETAIL